Insider Trading Activity For Corbus Pharmaceuticals (NASDAQ:CRBP)
Yuval Cohen , CEO of Corbus Pharmaceuticals (NASDAQ:CRBP) reportedly Bought 1,725 shares of the company’s stock at an average price of 5.85 for a total transaction amount of $10,091.25 SEC Form
Insider Trading History For Corbus Pharmaceuticals (NASDAQ:CRBP)
On 11/25/2014 Sean F Moran, CFO, bought 3,000 with an average share price of $3.05 per share and the total transaction amounting to $9,150.00.
On 11/25/2014 Mark Tepper, Insider, bought 2,000 with an average share price of $3.05 per share and the total transaction amounting to $6,100.00.
On 11/26/2014 Sean F Moran, CFO, bought 1,000 with an average share price of $3.05 per share and the total transaction amounting to $3,050.00.
On 11/26/2014 Barbara White, Insider, bought 13,400 with an average share price of $3.00 per share and the total transaction amounting to $40,200.00.
On 11/28/2014 Barbara White, Insider, bought 19,933 with an average share price of $3.00 per share and the total transaction amounting to $59,799.00.
On 12/1/2014 Barbara White, Insider, bought 16,448 with an average share price of $3.00 per share and the total transaction amounting to $49,344.00.
On 12/2/2014 Sean F Moran, CFO, bought 1,000 with an average share price of $3.03 per share and the total transaction amounting to $3,030.00.
Analyst Ratings History For Corbus Pharmaceuticals (NASDAQ:CRBP)
- On 11/30/2016 Aegis Reiterated Rating Buy with a price target of $12.00
- On 4/3/2017 JMP Securities Reiterated Rating Outperform with a price target of $20.00 ➝ $27.00
- On 1/19/2018 Raymond James Initiated Coverage of rating Outperform ➝ Outperform with a price target of $24.00
- On 3/13/2018 Noble Financial Reiterated Rating Buy
- On 5/10/2018 Cantor Fitzgerald Set Price Target of rating Buy with a price target of $32.00
Recent Trading Activity for Corbus Pharmaceuticals (NASDAQ:CRBP)
Shares of Corbus Pharmaceuticals closed the previous trading session at 6.50 up +0.20 3.17% with 326672 shares trading hands.